Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.40 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215169 | 0.98 | CYP1A2 (0.46) | CYP1A2CYP2C19KDM4EPKMGAA | |
| Pyrrole SCHEMBL7139666 | 0.89 | CYP1A2 (0.40) | CYP1A2CYP2C19KDM4EPKMGAA | |
| SCHEMBL26004856 | 0.85 | P2RY12 (0.44) | CYP1A2CYP2C19KDM4EPKMPOLB | |
| SCHEMBL21180775 | 0.85 | P2RY12 (0.44) | CYP1A2CYP2C19KDM4EPKMPOLB | |
| SCHEMBL12514045 | 0.85 | P2RY12 (0.44) | CYP1A2CYP2C19KDM4EPKMPOLB | |
| Hydrochloric Acid SCHEMBL7139668 | 0.84 | CYP1A2 (0.40) | CYP1A2CYP2C19KDM4EPKMGAA | |
| Hydrochloric Acid SCHEMBL30944505 | 0.80 | RXFP1 (0.41) | CYP1A2CYP2C19KDM4EMEN1KMT2A | |
| SCHEMBL7709312 | 0.79 | CYP1A2 (0.46) | CYP1A2CYP2C19KDM4EPKMPOLB | |
| SCHEMBL5121029 | 0.79 | RAB9A (0.49) | CYP1A2KDM4EGAAKMT2AALDH1A1 | |
| SCHEMBL9099149 | 0.79 | CYP1A2 (0.31) | CYP1A2CYP2C19PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | DESIGN THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250295632-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| WO-2025122764-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4539842-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025076181-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | DESIGN THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| CN-119677513-A | Methods and compounds for modulating genetic disease | 设计治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4522168-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20020065227-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002000262-A2 | MODULATION OF CHROMOSOME FUNCTION BY CHROMATIN REMODELING AGENTS | UNIVERSITE DE GENEVE (CH) | 2002-01-03 | — | — | WO | disclosed |
| US-6303312-B1 | MODIFYING CELL PHENOTYPE; MEDICAL RESEARCH AND THERAPY | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2001-10-16 | — | — | US | disclosed |
| WO-2001074898-A2 | CHARGED COMPOUNDS COMPRISING A NUCLEIC ACID BINDING MOIETY AND USES THEREFOR | GENESOFT, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-6143901-A | FORMINGA SPECIFIC COMPLEX BETWEEN A TARGET SEQUENCE OF DOUBLE STRANDED DNA AND AN OLIGOMER OR POLYMER OF N-METHYLPYRROLE CARBOXAMIDE AND N-METHYLIMIDAZOLE CARBOXAMID WHEREIN N-HETEROCYLCES ARE CONNCETED WITH AN AMINO ACID LINKING GROUP | GENESOFT, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6090947-A | Method for the synthesis of pyrrole and imidazole carboxamides on a solid support | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-07-18 | — | — | US | disclosed |
| CN-1260006-A | Formation of a Complex between double-stranded DNA and heterocyclic oligomer | CALIFORNIA INST OF TECHN (US) | 2000-07-12 | — | — | CN | disclosed |
| EP-0986539-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5998140-A | COMPLEXES OF CELL WITH OLIGOMER | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998049142-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | GAA 3302/4885GLA 2425/4885CYP1A2 2042/4885 |
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | CLN6, GATAD2B, MITF | GAA 19/4885GLA 1856/4885CYP1A2 4522/4885 |
| US-20250295632-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, CLN6, ATXN2L | GAA 28/4885GLA 422/4885CYP1A2 4699/4885 |
| US-20020065227-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | GAA 726/4885GLA 2264/4885CYP1A2 4885/4885 |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, ATXN10 | GAA 59/4885GLA 597/4885CYP1A2 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.